IE20000303A1 - Peptides for Therapeutic use - Google Patents
Peptides for Therapeutic useInfo
- Publication number
- IE20000303A1 IE20000303A1 IE20000303A IE20000303A IE20000303A1 IE 20000303 A1 IE20000303 A1 IE 20000303A1 IE 20000303 A IE20000303 A IE 20000303A IE 20000303 A IE20000303 A IE 20000303A IE 20000303 A1 IE20000303 A1 IE 20000303A1
- Authority
- IE
- Ireland
- Prior art keywords
- recited
- residue
- seq
- compound
- patient
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 185
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 29
- 230000001225 therapeutic effect Effects 0.000 title claims description 9
- 208000010399 Wasting Syndrome Diseases 0.000 claims abstract description 132
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 208000015181 infectious disease Diseases 0.000 claims abstract description 6
- 102000018594 Tumour necrosis factor Human genes 0.000 claims abstract 147
- 108050007852 Tumour necrosis factor Proteins 0.000 claims abstract 147
- 206010006895 Cachexia Diseases 0.000 claims abstract 76
- 208000011231 Crohn disease Diseases 0.000 claims abstract 73
- 102000014150 Interferons Human genes 0.000 claims abstract 73
- 108010050904 Interferons Proteins 0.000 claims abstract 73
- 102000000589 Interleukin-1 Human genes 0.000 claims abstract 73
- 108010002352 Interleukin-1 Proteins 0.000 claims abstract 73
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract 73
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract 73
- 208000026072 Motor neurone disease Diseases 0.000 claims abstract 73
- 229940079322 interferon Drugs 0.000 claims abstract 73
- 208000005264 motor neuron disease Diseases 0.000 claims abstract 73
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 73
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract 34
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 34
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract 34
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 235000018102 proteins Nutrition 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 125000000539 amino acid group Chemical group 0.000 claims description 46
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 239000012730 sustained-release form Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 423
- 150000001875 compounds Chemical class 0.000 claims 244
- 210000004027 cell Anatomy 0.000 claims 92
- 150000004665 fatty acids Chemical group 0.000 claims 63
- 125000003729 nucleotide group Chemical group 0.000 claims 45
- 206010061818 Disease progression Diseases 0.000 claims 38
- 230000005750 disease progression Effects 0.000 claims 38
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 claims 37
- 230000000840 anti-viral effect Effects 0.000 claims 24
- 102100027211 Albumin Human genes 0.000 claims 23
- 108010088751 Albumins Proteins 0.000 claims 23
- 235000014113 dietary fatty acids Nutrition 0.000 claims 23
- 229930195729 fatty acid Natural products 0.000 claims 23
- 239000000194 fatty acid Substances 0.000 claims 23
- 239000002773 nucleotide Substances 0.000 claims 23
- 230000002485 urinary effect Effects 0.000 claims 23
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 22
- 241001465754 Metazoa Species 0.000 claims 22
- 230000001580 bacterial effect Effects 0.000 claims 22
- 230000037396 body weight Effects 0.000 claims 22
- 229960002897 heparin Drugs 0.000 claims 22
- 229920000669 heparin Polymers 0.000 claims 22
- 241000238631 Hexapoda Species 0.000 claims 21
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 21
- 101710195585 Urinary protein 1 Proteins 0.000 claims 21
- 102000003848 Uteroglobin Human genes 0.000 claims 21
- 102100031083 Uteroglobin Human genes 0.000 claims 21
- 108090000203 Uteroglobin Proteins 0.000 claims 21
- 210000004962 mammalian cell Anatomy 0.000 claims 21
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 21
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 20
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 20
- 210000004899 c-terminal region Anatomy 0.000 claims 20
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 20
- 108010063045 Lactoferrin Proteins 0.000 claims 19
- 102100032241 Lactotransferrin Human genes 0.000 claims 19
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 19
- 229940078795 lactoferrin Drugs 0.000 claims 19
- 235000021242 lactoferrin Nutrition 0.000 claims 19
- 241000700605 Viruses Species 0.000 claims 9
- 238000001356 surgical procedure Methods 0.000 claims 7
- 206010028851 Necrosis Diseases 0.000 claims 5
- 230000017074 necrotic cell death Effects 0.000 claims 5
- 241000701022 Cytomegalovirus Species 0.000 claims 4
- 241000710831 Flavivirus Species 0.000 claims 4
- 241000710801 Rubivirus Species 0.000 claims 4
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 208000006454 hepatitis Diseases 0.000 claims 4
- 231100000283 hepatitis Toxicity 0.000 claims 4
- 238000002203 pretreatment Methods 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 241000700559 Molluscipoxvirus Species 0.000 claims 3
- 241000710778 Pestivirus Species 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 241001493065 dsRNA viruses Species 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 101150030352 Arsi gene Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 241000237519 Bivalvia Species 0.000 claims 1
- 238000011238 DNA vaccination Methods 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 102000004641 Fetal Proteins Human genes 0.000 claims 1
- 108010003471 Fetal Proteins Proteins 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 229940096437 Protein S Drugs 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000020639 clam Nutrition 0.000 claims 1
- 230000009429 distress Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims 1
- 229960003081 probenecid Drugs 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 abstract description 2
- 206010014824 Endotoxic shock Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 231100000444 skin lesion Toxicity 0.000 abstract 1
- 206010040882 skin lesion Diseases 0.000 abstract 1
- 208000016261 weight loss Diseases 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108090000426 Caspase-1 Proteins 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940099191 duragesic Drugs 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- -1 transdermal patch Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Prophylactic against cachexia, weight loss and wasting syndrome, as well as treatment for individuals displaying conditions associated with elevation of Tumour Necrosis Factor (TNF), Interleukin 1, Interleukin 2 and/or Interferon, can be achieved through the administration of peptides as specified herein. Examples of infections that are amenable to the use of peptides outlined herein, in this regard include Motor Neuron disease, Multiple Sclerosis, Crohn's disease, osteoporosis, arthritis, metastasis, coronary artery disease, liver cirrhosis, adult respiratory distress syndrome, inflammatory bowel diseases, sepsis, endotoxic shock, lung diseases, hypoxia reperfusion injury. In addition, peptides outlined herein, can be used as a neonatal administration to a baby either before or at delivery and, optionally, for the first several months of life, in order to prevent death, establish a reasonable foetal health profile, establish normal weight, lead to normal growth and/or reduce possible skin lesions.
Description
DESCRIPTION
The present invention relates to the therapeutic application of peptides outlined herein for their ability to prevent wasting syndrome. Treatment with peptides disclosed herein will provide longlasting protection from chemically induced carcinogenesis and breast cancer. Treatments with peptides disclosed herein will provide a potential therapy for pre-term labour inhibition in pregnancy.
Breast cancer is more frequent in nulliparous women, while its incidence is significantly reduced by full-term pregnancy. The fact that the protection conferred by full-term pregnancy is observed in women from different areas of the world and ethnic groups indicates that this protection does not result from extrinsic factors specific to a particular environment, genetic, or socio-economic setting, but rather from an intrinsic effect of parity on the biology of the breast. From the understanding of the unique actions of the peptides disclosed herein it is postulated that the use of peptides of this invention will induce the synthesis of inhibin, a secreted protein with tumor-suppressor activity. Peptides disclosed herein are envisaged to increase the expression of the programmed cell death (PCD) genes, testosterone repressed prostate message 2, Interleukin 1-beta-converting enzyme (ICE), induce apoptosis and downregulate cyclins. These peptides are envisaged to play a major role in the long-lasting protection, similar to that experienced by full-term pregnancy, from chemically induced carcinogenesis. These peptides may also mimic the biological process of full-term pregnancy and provide lifetime reduction in breast cancer risk. It is envisaged that therapeutic use of the peptide disclosed herein will exhibit potent inhibition of prostaglandin-induced pre-term delivery. This will provide a potential therapy for pre-term labour inhibition in human pregnancy. These peptides will induce functional maturation of the cortical thymocytes. These peptides will act as a factor regulating
antigen-independent differentiation of T-lymphocytes during pregnancy and accordingly enhance the immune system in embryogenesis.
The present invention relates to the use of peptides outlined herein in treatment of and prophylactic intervention during pregnancy to inhibit infection transfer between mother and offspring.
SUMMARY OF THE INVENTION
It is hereby claimed by the inventor that administration of peptides specified herein to human patients will have a range of therapeutic applications as identified above.
Pursuant to a preferred embodiment of the invention, the effective amount of peptides identified herein thus administered is such as to produce a circulating concentration of peptide sufficient to effect a response. According to another preferred embodiment, the effective amount is administered in a dosage ranging between about 10 and 20, 000 μg/ml of plasmas. Treatment according to the present invention can be effected when the subject is a neonate. Administration is carried our prior to and/or at delivery.
In accordance with another aspect of the present invention, at least one specific peptides of this invention is provided in a therapeutic, sustained-release form which is particularly well-suited for implementing the aforementioned therapy. Examples of the above are nasal spray, transdermal patch, implant or suppository.
A key aspect of the present invention is the fact that the disclosed peptides potentates or intensifies the effectiveness of the immune system. This immune-potentiating capability of
these within peptides can be exploited to therapeutic advantage in a number of specific ways which are identified above. The peptides of the present patent may play a vital role as therapeutics at early stage in the life of a infant.
Other variables will impact upon the essentially empirical endeavour of optimising peptide 5 dosage in the present invention. Accordingly, it may be an aspect of the present invention that peptides outlined herein be monitored, in conjunction with the observed indication of the infection being treated. Peptide plasma levels at least in the range 6.2. g/ml are desirable. Short-term therapy will enhance immune function.
The use of peptides in a sustained-release modality represents a preferred approach. One 10 sustained-release form of peptide is a transdermal peptide patch, after the fashion of the
DURAGESIC.TM. fentanyl patch. In this context, transdermal delivery of peptides has been accomplished iontophoretically or electroosmotically, i.e., under the influence of an electric field. See, for example, U. S. Pat. No. 4, 878, 892, No. 4, 940, 456, No. 5, 032, 109, No.5, 158, 537 and No. 5, 250, 023. The respective contents of these documents, as well as of the other publications cited in the present specification, are hereby incorporated by reference.
Another sustained-release form of peptide within the present invention is an implantable peptide delivery system. In the manner of the NORPLANT.TM. levonorgestrel implant, a type of device in this category employs passive release of peptide through a non-biodegradable, rate-limiting membrane element composed, for instance, of a hydrogel or a microporous polymer. See U.S.Pat. No. 5, 292, 515 and patent documents cited there, such as U.S. Pat. No.3, 993, 072, and U.S. Pat. No. 4, 959, 217. Another type of peptide implant contemplated by the present invention incorporates a pump function to administer the peptide. See, for instance, U.S. Pat. No. 5, 030,
216, No.5, 368, 588, No. 5, 370, 635 and No. 5, 391, 164. The pumping action can be osmotically driven or patient-activated, for example, or can be controlled by a servomechanism which allows for the titration of peptide and, hence, dosage adjustment in light of monitored parameters. The present invention comprehends treatment of individuals with peptides in instances where the immune system has been compromised or is to undergo compromise. Persons who could be treated in this context include, for example, cancer patients who are to start chemotherapy or irradiation which is expected to weaken or otherwise jeopardise their immune systems.
In appropriate formulations that are known and conventional to those skilled in the art, the administration of peptides by various routes of administration is contemplated, including intramuscular subcutaneous, transmucosal, transdermal and parenteral. As discussed above, administration of peptide is contemplated through a sustained-release drug delivery system, for example, transdermal skin patches and different types of implants. A bioavailable, sustained15 release oral formulation of peptide also should be possible. It should be understood that this detailed description, while indicating preferred embodiments of the invention, are given by way of illustration. Various changes and modifications within the spirit and scope of the invention will be apparent to those skilled in the art from the description.
It is clear for anyone skilled in the art that conservative variations of said polypeptides are also part of the present invention. The term “conservative variation” as used herein denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, and the like. The term “conservative variation” implies sequence - conservation or function - conservative variants.
Claims (1)
1. A method of treating wasting syndrome in a patient in need of such treatment, comprising administering to said patient at least one compound in an amount which is effective for said treatment, said compound comprising a peptide sequence selected from the group 10 consisting of: SEQ ID NO. 1 to SEQ ID NO. 134 conservative variants of SEQ ID NO. 1 to SEQ ID NO. 134 15 2. A method of treating wasting syndrome as recited in claim 1, wherein said at least one compound consists of: -a sequence selected from the group consisting of SEQ ED NO. 1 to SEQ ID NO. 134 20 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 134 , said part of a sequence having at least four amino acid residues; -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of 5 SEQ ID NO. 1 TO SEQ ID NO. 134 , said portion of a sequence having at least four amino acid residues. 3. A method of treating wasting syndrome as recited in claim 1, wherein said at least one 10 compound consists of: (1) a first residue consisting of: -a residue of a peptide sequence selected from the group consisting of SEQ ID 15 NO. 1 TO SEQ ID NO. 134 -a residue of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 20 -a residue of a conservative variant of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or «ρ Ο Ο Q ® -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 4. A method of treating wasting syndrome as recited in claim 3, wherein said at least one 10 adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 15 5. A method of treating wasting syndrome as recited in claim 3 or claim 4, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 20 6. A method of treating wasting syndrome as recited in any one of claims 3 - 5, wherein said peptide sequence residue consists of albumin, lactoferrin, alpha fetoprotein, urinary protein, urinary protein 1 and or uteroglobin. i 7. A method of treating wasting syndrome as recited in any one of claims 3-5, wherein said sugar residue consists of heparin. 8. A method of treating wasting syndrome as recited in any one of claims 3-5, wherein said fatty acid residue is selected from the group consisting of C 5 - C 20 fatty acid. 10 9. A method of treating wasting syndrome as recited in any one of claims 1-8, wherein said wasting syndrome is resultant from infection with a DNA virus, RNA virus, HIV, Kaposi’s Sarcoma-associated herpes virus, the viruses of the genus Molluscipoxvirus, the viruses of the genus hepatitis and/or the virus cytomegalovirus. 10. A method of treating wasting syndrome as recited in any one of claims 1-8, wherein said wasting syndrome is resultant from infection with a togaviruses, flaviviruses, rubiviruses, pestiviruses and/or hanaviruse. 11. A method of treating wasting syndrome as recited in any one of claims 1 - 10, wherein said amount of compound at least is sufficient to produce an elevation in T R count or T 4 count. 12. A method of treating wasting syndrome as recited in any one of claims 1-11, wherein said compound is administered to said patient in plasma, said compound being present in 5 said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 13. A method of treating wasting syndrome as recited in any one of claims 1-12, wherein 10 said compound is administered to said patient in a dosage in the range of from about 10pg to 20,000pg per kilogram of body weight of said patient. 14. A method of treating wasting syndrome as recited in any one of claims 1-13, wherein said patient is a neonate and said administering is effected prior to delivery of said 15 neonate and/or during delivery of said neonate. 15. A method of treating wasting syndrome as recited in any one of claims 1-14, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 16. A method of treating wasting syndrome as recited in claim 15, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 17. A method of treating wasting syndrome as recited in any one of claims 1-16, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 5 18. A method of treating wasting syndrome as recited in claim 17, wherein said anti-viral compound is a protease inhibitor and/or a reverse transcriptase inhibitor. 19. A method of treating wasting syndrome as recited in any one of claims 1-18, wherein said patient is a human. 20. A method of treating wasting syndrome as recited in any one of claims 1-19, wherein said patient is an animal. 21. A method of reducing the likelihood of wasting syndrome in a patient who is at risk of 15 suffering wasting syndrome, comprising administering to said patient at least one compound comprising a peptide sequence selected from the group consisting of: -SEQ ID NO. 1 TO SEQ ID NO. 134 -conservative variants of SEQ ID NO. 1 TO SEQ ID NO. 134 . 22. A method of reducing the likelihood of wasting syndrome as recited in claim 21, wherein at least one compound consists of: -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID 5 NO. 134 , said part of a sequence having at least four amino acid residues; -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or 10 -a conservative variant of a portion of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said portion of a sequence having at least four amino acid residues. 15 23. A method of reducing the likelihood of wasting syndrome as recited in claim 21, wherein at least one compound consists of: (1) a first residue consisting of: 20 -a residue of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a conservative variant of a peptide sequence selected from the group 5 consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and (2) at least one adjunct residue, at least one adjunct residue being attached to said first residue. 15 24. A method of reducing the likelihood of wasting syndrome as recited in claim 23, wherein said compounds for the invention, at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 25. A method of reducing the likelihood of wasting syndrome as recited in claim 23 or claim 24, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 26. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 23 - 25, wherein said peptide sequence residue consists of albumin, lactoferrin, alpha fetoprotein, urinary protein, urinary protein 1 and or uteroglobin. 10 27. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 23 - 25, wherein said sugar residue consists of heparin. 28. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 23 - 25, wherein said fatty acid residue is selected from the group consisting of C, - C 20 15 fatty acid. 29. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 21 - 28, wherein said virus is selected from the group consisting of RNA virus, DNA virus, HIV, Kaposi’s Sarcoma-associated herpes virus, the viruses of the genus 20 Molluscipoxvirus, the viruses of the genus hepatitis, and the virus cytomegalovirus. ίί 30. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 21 - 28, wherein said virus is selected from the group consisting of togaviruses, flaviviruses, rubiviruses and pestivimses. 31. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 21 - 30, wherein said amount of at least one compound is sufficient to produce an elevation in T o count or T„ count. 8 4 32. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 21 - 31, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 33. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 21 - 32, wherein said compound is administered to said patient in a dosage in the range of from about 10pg to 20, 000pg per kilogram of body weight of said patient. 34. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 21 - 33, wherein said patient is a neonate and said administering is effected prior to delivery of said neonate and/or during delivery of said neonate. I 35. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 21 - 34, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 36. A method of reducing the likelihood of wasting syndrome as recited in claim 35, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 10 37. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 21 - 36, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 38. A method of reducing the likelihood of wasting syndrome as recited in claim 37, wherein 15 said anti-viral compound is a protease inhibitor or a reverse transcriptase inhibitor. 39. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 21 - 38, wherein said patient is a human. 20 40. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 21 - 39, wherein said patient is an animal. A method of reducing the likelihood of cachexia in a patient who is about to undergo surgery, comprising administering to said patient, shortly before said surgery is performed, at least one compound comprising a peptide sequence selected from the group consisting of: -SEQ ID NO. 1 TO SEQ ID NO. 134 -conservative variants of SEQ ID NO. 1 TO SEQ ID NO. 134 . 10 42. A method of reducing the likelihood of cachexia as recited in claim 41, wherein said at least one compound consists of: -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 15 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said part of a sequence having at least four amino acid residues; -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said portion of a sequence having at least four amino acid residues. u 0 u 43. A method of reducing the likelihood of cachexia as recited in claim 41, wherein said at least one compound consists of: 5 (1) a first residue consisting of: -a residue of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 10 -a residue of a part of a peptide sequence selected from the group consisting of SEQ ED NO. 1 TO SEQ ID NO. 134 -a residue of a conservative variant of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and 20 (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 44. A method of reducing the likelihood of cachexia as recited in claim 43, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid 5 residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 45. A method of reducing the likelihood of cachexia as recited in claim 43 or claim 44, wherein said at least one adjunct residue is covalently bonded to said first residue at a C10 terminal or an N-terminal end of said first residue. 46. A method of reducing the likelihood of cachexia as recited in any one of claims 43 - 45, wherein said peptide sequence residue consists of albumin, lactoferrin, alpha 15 fetoprotein, urinary protein, urinary protein 1 and/or uteroglobin. 47. A method of reducing the likelihood of cachexia as recited in any one of claims 43 - 45, wherein said sugar residue consists of heparin. 48. A method of reducing the likelihood of cachexia as recited in any one of claims 43 - 45, wherein said fatty acid residue is selected from the group consisting of C, - C’ 2O fatty acid. 49. A method of reducing the likelihood of cachexia as recited in any one of claims 41 - 48, wherein said amount of at least one compound is sufficient to produce an elevation in T count or T„ count. 50. A method of reducing the likelihood of cachexia as recited in any one of claims 41 - 49, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 51. A method of reducing the likelihood of cachexia as recited in any one of claims 41 - 50, wherein said compound is administered to said patient in a dosage in the range of from about 10pg to 20, 000pg per kilogram of body weight of said patient. 15 52. A method of reducing the likelihood of cachexia as recited in any one of claims 41 - 51, wherein said patient is a neonate and said administering is effected prior to delivery of said neonate and/or during delivery of said neonate. 53. A method of reducing the likelihood of cachexia as recited in any one of claims 41 - 52, 20 wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 54. A method of reducing the likelihood of cachexia as recited in claim 53, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 55. A method of reducing the likelihood of cachexia as recited in any one of claims 41 - 54, 5 further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 56. A method of reducing the likelihood of cachexia as recited in claim 55, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 57. A method of reducing the likelihood of cachexia as recited in any one of claims 41 - 56, wherein said patient is a human. 58. A method of reducing the likelihood of cachexia as recited in any one of claims 41 - 57, 15 wherein said patient is an animal. 59. A method of treating cachexia in a patient who has recently undergone surgery, comprising administering to said patient at least one compound comprising a peptide sequence selected from the group consisting of: -SEQ ID NO. 1 TO SEQ ID NO. 134 -conservative variants of SEQ ID NO. 1 TO SEQ ID NO. 134 . 60. A method of treating cachexia as recited in claim 59, wherein said at least one compound consists of: -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 5 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said part of a sequence having at least four amino acid residues; -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134, said portion of a sequence having at least four amino acid residues. 15 61. A method of treating cachexia as recited in claim 59, wherein said at least one compound consists of: (1) a first residue consisting of: -a residue of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a conservative variant of a peptide sequence selected from the group 5 consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 62. A method of treating cachexia as recited in claim 61, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 63. A method of treating cachexia as recited in claim 61 or claim 62, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an Nterminal end of said first residue. ti ti 64. A method of treating cachexia as recited in any one of claims 61 - 63, wherein said peptide sequence residue consists of albumin, lactoferrin, alpha fetoprotein urinary protein, urinary protein 1 and/or uteroglobin 65. A method of treating cachexia as recited in any one of claims 61 - 63, wherein said sugar residue consists of heparin. 66. A method of treating cachexia as recited in any one of claims 61 - 63, wherein said fatty 10 acid residue is selected from the group consisting of C, - C 20 fatty acid. 67. A method of treating cachexia as recited in any one of claims 59 - 66, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 count. 68. A method of treating cachexia as recited in any one of claims 59 - 67, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 69. A method of treating cachexia as recited in any one of claims 59 - 68, wherein said compound is administered to said patient in a dosage in the range of from about 1 Opg to 20, OOOpg per kilogram of body weight of said patient. IQ. A method of treating cachexia as recited in any one of claims 59 - 69, wherein said patient is suffering from Alzheimer’s Disease. 5 71. A method of treating cachexia as recited in any one of claims 59 - 70, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 72. A method of treating cachexia as recited in claim 71, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 73. A method of treating cachexia as recited in any one of claims 59 - 72, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 15 74. A method of treating cachexia as recited in claim 73, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 75. A method of treating cachexia as recited in any one of claims 59 - 74, wherein said patient is a human. 76. A method of treating cachexia as recited in any one of claims 59 - 75, wherein said patient is an animal. ΊΊ. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease in a patient in need of such treatment, comprising administering to said patient at least one compound comprising a peptide sequence selected from the group consisting of: 5 -SEQ ID NO. 1 TO SEQ ID NO. 134 -conservative variants of SEQ ED NO. 1 TO SEQ ID NO. 134 . 78. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 77, wherein said at least one compound consists of: -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said part of a sequence having at least four amino acid residues; -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ED NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of 20 SEQ ED NO. 1 TO SEQ ID NO. 134 , said portion of a sequence having at least four amino acid residues. 7. 79. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 77, wherein said at least one compound consists of: (1) a first residue consisting of: -a residue of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a part of a peptide sequence selected from the group consisting of 10 SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a conservative variant of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or 15 -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 80. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 79, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue 5 comprising at least one nucleotide residue. 81. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 79 or claim 80, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 82. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 79 - 81, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 83. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 79 - 81, wherein said sugar residue consists of heparin. 84. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 20 recited in any one of claims 79-81, wherein said fatty acid residue is selected from the group consisting of Cj - C 20 fatty acid. 85. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 77 - 84, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4> 5 86. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 77 - 85, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 10 87. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 77 - 86, wherein said compound is administered to said patient in a dosage in the range of from about 10pg to 20, OOOpg per kilogram of body weight of said patient. 15 88. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 77 - 87, wherein said patient is suffering from wasting syndrome or is at risk of suffering from wasting syndrome. 89. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 20 recited in any one of claims 77 - 88, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 90. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 89, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 5 91. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 77 - 90, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 92. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 10 recited in claim 91, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 93. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 77 - 92, wherein said patient is a human. 94. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 77 - 93, wherein said patient is an animal. 95. A method of ameliorating immune damage and/or disease progression in a patient 20 suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease, comprising administering to said patient at least one compound in an amount which is effective for said ameliorating immune damage and/or disease progression, said compound comprising a peptide sequence selected from the group consisting of: -SEQ ID NO. 1 TO SEQ ID NO. 134 -conservative variants of SEQ ID NO. 1 TO SEQ ID NO. 134 . 5 96. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 95, wherein said at least one compound consists of: -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said part of a sequence having at least four amino acid residues; -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 15 1 TO SEQ ID NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said portion of a sequence having at least four amino acid residues. 97. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 95, wherein said at least one compound consists of: 5 (1) a first residue consisting of: -a residue of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 10 -a residue of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a conservative variant of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 98. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 97, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 5 99. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 97 or claim 98, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 10 100. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 97 - 99, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 101. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 97 - 99, wherein said sugar residue consists of heparin. 20 102. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 97 - 99, wherein said fatty acid residue is selected from the group consisting of C, - C 20 fatty acid. 103. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 95 - 102, wherein said amount of at least one compound is 5 sufficient to produce an elevation in T g count or T 4 count. 104. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 95 - 103, wherein said compound is administered to said 10 patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 105. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 15 recited in any one of claims 95 - 104, wherein said compound is administered to said patient in a dosage in the range of from about 10pg to 20, 000gg per kilogram of body weight of said patient. 106. A method of ameliorating immune damage and/or disease progression in a patient 20 suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 95 - 105, wherein said patient is showing signs of wasting syndrome. 107. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 95 - 106, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 108. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 107, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 109. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 95 - 108, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 110. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 109, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 111. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 95 - 110, wherein said patient is a human. 112. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 95-111, wherein said patient is an animal. 113. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon in a patient comprising administering a compound comprising a peptide sequence selected from the group consisting of: 10 -SEQ ID NO. 1 TO SEQ ID NO. 134 -conservative variants of SEQ ID NO. 1 TO SEQ ID NO. 134 . 114. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 113, wherein said at least one 15 compound consists of: -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID 20 NO. 134 , said part of a sequence having at least four amino acid residues; -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said portion of a sequence having at least four amino acid residues. 115. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 113, wherein said at least one compound consists of: 10 (1) a first residue consisting of: -a residue of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 15 -a residue of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a conservative variant of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and fi (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 116. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 115, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue 10 and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 117. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 115 or claim 116, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an 15 N-terminal end of said first residue. 118. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 115 - 117, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, 20 urinary protein, urinary protein 1 and/or uteroglobin. 119. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 115 - 117, wherein said sugar residue consists of heparin. 5 120. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 115 - 117, wherein said fatty acid residue is selected from the group consisting of Cj - C 2Q fatty acid. 121. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), 10 Interleukin 1 or 2 and/or Interferon as recited in any one of claims 113 - 120, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T. count. 122. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), 15 Interleukin 1 or 2 and/or Interferon as recited in any one of claims 113 - 121, wherein said compowd is administered to said nx.er'm plasma, said compound being present in said plasma m a concentration of from about 10 io about 5000pg of said compound per ml of plasma. 20 123. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 113-122, wherein said compound is administered to said patient in a dosage in the range of from about 10pg to 20, OOOpg per kilogram of body weight of said patient. 124. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 113 - 123, wherein said patient is a neonate and said administering is effected prior to delivery of said 5 neonate and/or during delivery of said neonate. 125. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 113 - 124, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell 10 line. 126. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 125, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 127. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and or interferes as reeled m any one of claims 113 - 126, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 128. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 127, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 4Ϊ 129. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 113 - 128, wherein said patient is a human. 130. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 113 - 129, wherein said patient is an animal. 10 131. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 113 - 130, wherein said condition may cause wasting syndrome. 132- A method of reducing the possibility of onset of conditions associated with elevated 15 Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and or Interferon in a patient who is at risk for developing such conditions comprising administering a compound comprising a peptide sequence selected from the group consisting of: -SEQ ID NO. 1 TO SEQ ID NO. 134 20 -conservative variants of SEQ ID NO. 1 TO SEQ ID NO. 134 . 133. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 132, wherein said at least one compound consists of: 5 -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said part of a sequence having at least four amino acid residues; 10 -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ED NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of SEO ID NO. 1 TO SEO ID NO. 134 . said portion of a sequence having ai least four 15 amino acid residues. 134. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 132, wherein said at least one compound consists of: (1) a first residue consisting of: -a residue of a peptide sequence selected from the group consisting of SEQ ED NO. 1 TO SEQ ID NO. 134 -a residue of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a conservative variant of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and (2) at least one adjunct residue, said at leas osc rssa&at bessg attached to sscd firs; residue. 135. A method of reducing the tOssibinty of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 134, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. y Π τ ? ii '£( C’i 136. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 134 or claim 135, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-tenninal end of said first residue. 137. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 134 - 136, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 138. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 134 - 136, wherein said sugar residue consists of heparin. 15 139- A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 134 - 136, wherein said fatty acid residue is selected from the group consisting of C, - C 20 fatty acid. 20 140. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 132 - 139, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 count. ο η ι 141. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 132 - 140, wherein said compound is administered to said patient in plasma, 5 said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 142. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one 10 of claims 132 - 141, wherein said compound is administered to said patient in a dosage in the range of from about 10pg to 20, OOOpg per kilogram of body weight of said patient. 143. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), interleukin 1 or 2 and/or Interferon as recited in any one 15 of claims 132 - 142, wherein said patient is a neonate and said administering is effected prior to delivery' of said neonate and/or during delivery of said neonate. 144. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one 20 of claims 132 - 143, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 145. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNT), Interleukin 1 or 2 and/or Interferon as recited in claim 144, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 146. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 132 - 145, further comprising administering to said patient at least one antiviral compound and/or at least one immune altering compound. 147. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 146, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 148. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 132 - 147, wherein said patient is a human. 20 149. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 132- 148, wherein said patient is an animal. 150. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 132 - 149, wherein said condition may lead to wasting snydrome. 5 151. A method of reducing the possibility of pre-term labour in a patient by administering to said patient a compound comprising a peptide sequence selected from the group consisting of: -SEQ ID NO. 1 TO SEQ ID NO. 134 10 -conservative variants of SEQ ID NO. 1 TO SEQ ID NO. 134 . 152. A method of reducing the possibility of pre-term labour as recited in claim 151, wherein said at least one compound consists of: 15 -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said part of a sequence having at least four amino acid residues; 20 -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said portion of a sequence having at least four amino acid residues. 5 153. A method of reducing the possibility of pre-term labour as recited in claim 151, wherein said at least one compound consists of: (1) a first residue consisting of: 10 -a residue of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a conservative variant of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a residue of a conservative variant of a part of a peptide sequence selected from 20 the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 154. A method of reducing the possibility of pre-term labour as recited in claim 153, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide 5 sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue, 155. A method of reducing the possibility of pre-term labour as recited in claim 153 or claim 10 154, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 156. A method of reducing the possibility of pre-term labour as recited in any one of claims 153 - 155, wherein said peptide sequence residue consists of albumin, lactoferrin or 15 alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 157. A method of reducing the possibility of pre-term labour as recited in any one of claims 153 - 155, wherein said sugar residue consists of heparin. 20 158. A method of reducing the possibility of pre-term labour as recited in any one of claims 153 - 155, wherein said fatty acid residue is selected from the group consisting of C, - C 20 fatty acid. 159. A method of reducing the possibility of pre-term labour as recited in any one of claims 151 - 158, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 count of at least about 10% over pre-treatment levels in said patient after one month of therapy. 160. A method of reducing the possibility of pre-term labour as recited in any one of claims 151 - 159, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 161. A method of reducing the possibility of pre-term labour as recited in any one of claims 151 - 160, wherein said compound is administered to said patient in a dosage in the range of from about 1 Opg to 20, OOOpg per kilogram of body weight of said patient. 15 162. A method of reducing the possibility of pre-term labour as recited in any one of claims 151 - 161, wherein said patient is at risk of delivering due to side effects of other medications. 163. A method of reducing the possibility of pre-term labour as recited in any one of claims 20 151 - 162, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 164. A method of reducing the possibility of pre-term labour as recited in claim 163, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 5 165. A method of reducing the possibility of pre-term labour as recited in any one of claims 151 - 164, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 166. A method of reducing the possibility of pre-term labour as recited in claim 165, wherein 10 said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 167. A method of reducing the possibility of pre-term labour as recited in any one of claims 151-166, wherein said patient is a human. 15 168. A method of reducing the possibility of pre-term labour as recited in any one of claims 151 -167, wherein said patient is an animal. 169. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome in a patient in need of such treatment comprising administering to said patient at least one 20 compound comprising a peptide sequence selected from the group consisting of: -SEQ ID NO. 1 TO SEQ ID NO. 134 -conservative variants of SEQ ID NO. 1 TO SEQ ID NO. 134 . 170. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in claim 169, wherein said at least one compound consists of: 5 -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said part of a sequence having at least four amino acid residues; 10 -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said portion of a sequence having at least four 15 amino acid residues. 171. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in claim 169, wherein said at least one compound consists of: 20 (1) a first residue consisting of: -a residue of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 5 -a residue of a conservative variant of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 15 172. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in claim 171, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 173. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in claim 171 or claim 172, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 174. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 171 - 173, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or 5 uteroglobin. 175. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 171-173, wherein said sugar residue consists of heparin. 10 176. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 171 - 173, wherein said fatty acid residue is selected from the group consisting of Cj - C 20 fatty acid. 177. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as 15 recited in any one of claims 169 - 176, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 count 178. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 169 - 177, wherein said compound is administered to said 20 patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 179. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 169 - 178, wherein said compound is administered to said patient in a dosage in the range of from about 10pg to 20, OOOpg per kilogram of body weight of said patient. 180. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 169 - 179, wherein said patient is has elevated Tumour Necrosis Factor. 10 181. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 169 - 180, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 182. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as 15 recited in claim 181, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell Sue. 183. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 169 - 182, further comprising administering to said patient at 20 least one anti-viral compound and/or at least one immune altering compound. 184. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in claim 183, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 5 185. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 169- 184, wherein said patient is a human. 186. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 169- 185, wherein said patient is an animal. 187. A method of treating wasting syndrome in a patient in need of such treatment, comprising administering to said patient at least one compound in an amount which is effective for said treatment of said wasting syndrome, said compound comprising a peptide sequence which binds to antibody to clara cell protem. 188. A method of treating wasting syndrome as recited in claim 187, wherein said al least one compound consists of said sequence which binds to antibody to clara cel! protem. 189. A method of treating wasting syndrome as recited in claim 187, wherein said at least one 20 compound consists of: (1) a first residue consisting of said sequence which binds to antibody to clara cell protein; and (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 190. A method of treating wasting syndrome as recited in claim 189, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 191. A method of treating wasting syndrome as recited in claim 189 or claim 190, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 15 192. A method of treating wasting syndrome as recited in any one of claims 189 - 191, wherein said peptide sequence residue consists of albumin, Iactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 193. A method of treating wasting syndrome as recited in any one of claims 189 - 191, 20 wherein said sugar residue consists of heparin. 194. A method of treating wasting syndrome as recited in any one of claims 189 - 191, wherein said fatty acid residue is selected from the group consisting of C, - C 20 fatty acid. 195. A method of treating wasting syndrome as recited in any one of claims 187 - 194, wherein said wasting syndrome is resultant from a wasting syndrome. 196. A method of treating wasting syndrome as recited in any one of claims 195, wherein said virus is selected from the group consisting of togaviruses, flaviviruses, rubiviruses and pestiviruses, HIV, herpes virus, molluscipoxvirus, hepatitis and/or cytomegalovirus 197. A method of treating wasting syndrome as recited in any one of claims 187 - 196, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 count of at least about 10% over pre-treatment levels in said patient after one month of therapy. 198. A method of treating wasting syndrome as recited in any one of claims 187 - 197, wherein said compound is administered to said patient in plasma, said compound being prcseni in said plasma in a coocentratioo of from about 10 to about 5000pg of said compound per ml of plasma. 199. A method of treating wasting syndrome as recited in any one of claims 187 - 198, wherein said compound is administered to said patient in a dosage in the range of from about 10pg to 20, OOOpg per kilogram of body weight of said patient. 200. A method of treating wasting syndrome as recited in any one of claims 187 - 199, wherein said patient is a neonate and said administering is effected prior to delivery of said neonate and/or during delivery of said neonate. 5 201. A method of treating wasting syndrome as recited in any one of claims 187 - 200, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 202. A method of treating wasting syndrome as recited in claim 201, wherein said 10 recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 203. A method of treating wasting syndrome as recited in any one of claims 187 - 202, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 204. A method of treating wasting syndrome as recited in claim 203, wiserem Site immune altering compound is a ramt+w·· inhitHtor or a reverse transcriptase inhibitor. 205. A method of treating wasting syndrome as recited in any one of claims 187 - 204, 20 wherein said patient is a human. 206. A method of treating wasting syndrome as recited in any one of claims 187 - 205, wherein said patient is an animal. 207. A method of reducing the likelihood of wasting syndrome in a patient who is at risk for suffering viral infection, comprising administering to said patient at least one compound, said compound comprising a peptide sequence which binds to antibody to clara cell 5 protein. 208. A method of reducing the likelihood of wasting syndrome as recited in claim 207 wherein said at least one compound consists of said sequence which binds to antibody to clara cell protein. 209. A method of reducing the likelihood of wasting syndrome as recited in claim 207, wherein said at least one compound consists of: (i) a first residue consisting of said sequence which hinds to antibody to clara cell 15 protein, and m asast « xsgt&xa residue, said at least one adjunct residue being attached to said first residue. 210. A method of reducing the likelihood of wasting syndrome as recited in claim 209, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 211 A method of reducing the likelihood of wasting syndrome as recited in claim 209 or claim 24, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 212. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 209 - 211, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 213. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 209 - 211, wherein said sugar residue consists of heparin. 214. A method of reducing the likelihood of wastiog as recited in any one of claims 2. Ό9 - 2Π. wherein said fatty acid fss&se -s sesecsse --νκη fee group consisting of C s - 215. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 207 - 209, wherein said wasting syndrome is resultant from viral/bacterial infection. 216. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 207 - 209, wherein said viral infection caused by togaviruses, flaviviruses, rubiviruses and pestiviruses, HIV, Herpes, hepatitis and /or cytomegalovirus. 3. 5 217. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 207 - 216, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 count. 218. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 4. 10 207 - 217, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 219. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 15 20“ - 21S. wherein said compound is administered to said patient in a dosage in the range of from about JOpg & osogmn of body weight of said pattern. 220. A metnod of rednemg the iaescnsxd of wostmg syndrome as recited m any one of claims 207 - 219, wherein said patient is a neonate and said administering is effected prior to 20 delivery of said neonate and/or during delivery of said neonate. ,t= Ο 0 Q Π 3 i, 3m·* 221. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 207 - 220, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 5 222. A method of reducing the likelihood of wasting syndrome as recited in claim 221, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 223. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 10 207 - 222, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 224. A method of reducing the likelihood of wasting syndrome as recited in claim 223, wherein said immune auerine compound is a protease inhibitor or a reverse transcriptase 22i .* «*· .'βΛβΚΜι w .aiEeiiaooc cs *3·κ®$ syaeraeat as necsssac aey -.«as: aa 20“ - 224, wherein said patient is a human. 20 226. A method of reducing the likelihood of wasting syndrome as recited in any one of claims 207 - 225, wherein said patient is an animal. 227. . 228. 229. 230. A method of reducing the likelihood of cachexia in a patient who is about to undergo surgery, comprising administering to said patient, shortly before said surgery is performed, at least one compound in an amount which is effective for said reducing the likelihood of cachexia, said compound comprising a peptide sequence which binds to antibody to clara cell protein. A method of reducing the likelihood of cachexia as recited in claim 227, wherein said at least one compound consists of said sequence which binds to antibody to clara cell protein. A method of reducing the likelihood of cachexia as recited in claim 227, wherein said at least one compound consists of: (1) a first residue consisting of said sequence which binds to antibody to clara cell protein, and (2) ai least one adjunct residue. A raxooc or reoccurs me likelihood of cachexia as recited in claim 229, wherein said at least one rexriue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 231. A method of reducing the likelihood of cachexia as recited in claim 229 or claim 230, wherein said at least one adjunct residue is covalently bonded to said first residue at a Cterminal or an N-terminal end of said first residue. 5 232. A method of reducing the likelihood of cachexia as recited in any one of claims 229 231, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 233. A method of reducing the likelihood of cachexia as recited in any one of claims 229 10 231, wherein said sugar residue consists of heparin. 234. A method of reducing the likelihood of cachexia as recited in any one of claims 229 231, wherein said fatty acid residue is selected from the group consisting of C, - C 20 fatty acid. 235. A method of reducing the likelihood of m recited in any one of claims 227 234, wherein sad amount of at least one conmeuzd u. sufficient to produce an elevation in T e count or T. count 20 236. A method of reducing the likelihood of cachexia as recited in any one of claims 227 235, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. £Q Q0 30 3 237. A method of reducing the likelihood of cachexia as recited in any one of claims 227 - 236, wherein said compound is administered to said patient in a dosage in the range of from about 10pg to 20, OOOpg per kilogram of body weight of said patient. «? 238. A method of reducing the likelihood of cachexia as recited in any one of claims 227 - 237, wherein said patient is suffering from Alzheimer’s disease. 239. A method of reducing the likelihood of cachexia as recited in any one of claims 227 - 10 238, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 240. A method of reducing the likelihood of cachexia as recited in claim 239, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 241. A method of reducing the hkehhood of cachexia as rcciied in any one of charms 227 - 240, further composing admmistmng to said pan-er* « least one anri-vr»* and/or at least one immune altering compound. 20 242. A method of reducing the likelihood of cachexia as recited in claim 241, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. IF Ο 243. A method of reducing the likelihood of cachexia as recited in any one of claims 227 242, wherein said patient is a human. 244. A method of reducing the likelihood of cachexia as recited in any one of claims 227 5 243, wherein said patient is an animal. 245. A method of treating cachexia in a patient who has recently undergone surgery, comprising administering to said patient at least one compound in an amount which is effective for said treating cachexia, said compound comprising a peptide sequence which 10 binds to antibody to clara cell protein. 246. A method of treating cachexia as recited in claim 245, wherein said at least one compound consists of said sequence which binds to antibody to Clara cell protein. 15 247. A method of treating cachexia as recited in claim 245, wherein said at least one compound consists of: (1) said sequence which binds to antibody to Clara cell protein; and (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 248. A method of treating cachexia as recited in claim 247, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue IE Ο 0 Q 3 Ο 3 comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 249. A method of treating cachexia as recited in claim 247 or claim 248, wherein said at least 5 one adjunct residue is covalently bonded to said first residue at a C-terminal or an Nterminal end of said first residue. 250. A method of treating cachexia as recited in any one of claims 247 - 249, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary 10 protein, urinary protein 1 and/or uteroglobin. 251. A method of treating cachexia as recited in any one of claims 247 - 249, wherein said sugar residue consists of heparin. 15 252. A method of treating cachexia as recited in any one of claims 247 - 249, wherein said fatty acid residue is selected from the group consisting of C } - C 20 fatty acid. 253. A method of treating cachexia as recited in any one of claims 245 - 252, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 20 count of at least about 10% over pre-treatment levels in said patient after one month of therapy. 254. A method of treating cachexia as recited in any one of claims 245 - 253, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma, 255. A method of treating cachexia as recited in any one of claims 245 - 254, wherein said compound is administered to said patient in a dosage in the range of from about 1 Opg to 20, OOOpg per kilogram of body weight of said patient. 256. A method of treating cachexia as recited in any one of claims 245 - 255, wherein said patient is a neonate and said administering is effected prior to delivery of said neonate and/or during delivery of said neonate. 15 257. A method of treating cachexia as recited in any one of claims 245 - 256, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 258. A method of treating cachexia as recited in claim 257, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 259. A method of treating cachexia as recited in any one of claims 245 - 258, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 260. A method of treating cachexia as recited in claim 259, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 5 261. A method of treating cachexia as recited in any one of claims 245 - 260, wherein said patient is a human. 262. A method of treating cachexia as recited in any one of claims 245 - 261, wherein said patient is an animal. 263. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease in a patient in need of such treatment, comprising administering to said patient at least one compound comprising a peptide sequence which binds to antibody to clara cell protein. 15 264. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 263, wherein said at least one compound consists of said sequence which binds to antibody to clara cell protein. 265. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 20 recited in claim 263, wherein said at least one compound consists of: (1) a first residue consisting of said sequence which binds to antibody to clara cell protein; and 1E0 0 03 0 3 (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 266. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 5 recited in claim 265, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 10 267. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 265 or claim 266, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 268. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 15 recited in any one of claims 265 - 267, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 269. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 20 recited in any one of claims 265 - 267, wherein said sugar residue consists of heparin. 270. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 265 - 267, wherein said fatty acid residue is selected from the group consisting of Cj - C 20 fatty acid. 5 271. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 263 - 270, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 count. 272. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 10 recited in any one of claims 263 - 271, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 273. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 15 recited in any one of claims 263 - 272, wherein said compound is administered to said patient in a dosage in the range of from about lOpg to 20, OOOpg per kilogram of body weight of said patient. 274. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 20 recited in any one of claims 263 - 273, wherein said patient is a neonate and said administering is effected prior to delivery of said neonate and/or during delivery of said neonate. 275. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 263 - 274, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 276. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 275, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 10 277. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 263 - 276, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 15 278. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 277, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 279. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 20 recited in any one of claims 263 - 278, wherein said patient is a human. 280. A method of treating Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 263 - 279, wherein said patient is an animal. 281. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease, comprising administering to said patient at least one compound comprising a peptide 5 sequence which binds to antibody to clara cell protein. 282. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 281, wherein said at least one compound consists of said sequence which 10 binds to antibody to clara cell protein. 283. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 281, wherein said at least one compound consists of: 15 (1) a first residue consisting of said sequence which hinds to antibody to clara cell protein; and (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 20 284. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 283, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 5 285. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 283 or claim 284, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 10 286. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 283 - 285, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 287. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 283 - 285, wherein said sugar residue consists of heparin. 20 288. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 283 - 285, wherein said fatty acid residue is selected from the group consisting of C, - C 20 fatty acid. 289. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 281 - 288, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 count. 290. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 281 - 289, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from 10 about 10 to about 5000pg of said compound per ml of plasma. 291. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis andor Crohn’s disease as recited in any one of claims 281 - 290, wherein said compound is administered to said 15 panent in a dosage in the range of from about 10pg to 20, OOOug per kilogram of body weight of said patient 292. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as 20 recited in any one of claims 281 - 291, wherein said patient is suffering from wasting syndrome. 293. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 281 - 292, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 294. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in claim 293, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 295. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 281 - 294, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 296. A method of ameliorating immune damage and/or disease progression in a pat:errr suffering from Motor Neuron disease. Multiple Sclerosis and/or Crohn’s disease as recited in claim 295, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 297. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 281 - 296, wherein said patient is a human. 298. A method of ameliorating immune damage and/or disease progression in a patient suffering from Motor Neuron disease, Multiple Sclerosis and/or Crohn’s disease as recited in any one of claims 281 - 297, wherein said patient is an animal. 299. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon in a patient in need of such treatment, comprising administering one or more compound comprising a peptide sequence which binds to antibody to clara cell protein. 300. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 299, wherein said at least one compound consists of said sequence which binds to antibody to clara cell protein. 15 301. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 andor Interferon as recited in claim 299, wherein said at least one compound consists of: (1) a first residue consisting of said sequence which binds to antibody to clara cell protein; and 20 (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 302. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 301, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue 5 and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 303. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 301 or claim 302, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an 10 N-terminal end of said first residue. 304. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of dasms r ?O3, wherein wd peptide sequence residue consists of albumin, bctofcru·.· v 4. ““2 fese protein, 15 urinary protein, urinary proton 1 andor uteroglofc. 305. A method of treating conditions associated with elevated T urrnfuw Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 301 - 303, wherein said sugar residue consists of heparin. 306. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 301 - 303, wherein said fatty acid residue is selected from the group consisting of Cj - C 20 fatty acid. IE Ο Ο Ο 3 Ο 3 307. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 299 - 306, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 count. 308. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 299 - 307, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per 10 ml of plasma. 309. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), interleukin I or 2 and or h-rerfaoc as recited in any one of claims 299 - 308, wherein said compound is admirusisred to ssd in a desugs the range of from about 15 I Ottg to 20, OOOpg per kilogram ofbody wes^rt of said palienL 310. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 299 - 309, wherein said patient is a neonate and said administering is effected prior to delivery of said 20 neonate and/or during delivery of said neonate. 311. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 299 - 310, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 312. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 311, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 10 313. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 299 - 312, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 15 3 ί 4 A method of treating ccesiiscsa associated with elevated Turoeur Necrosas Factor (TNF J, interleukin 1 or 2 and/or interferon as reeded in claim 313, wherein said immune altering compound is a protease inhibitor or a “ crcc transcriptase inhibitor. 315. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), 20 Interleukin 1 or 2 and/or Interferon as recited in any one of claims 299 - 314, wherein said patient is a human. 316. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 299 - 315, wherein said patient is an animal. 5 317. A method of treating conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 299 - 316, wherein said condition may cause wasting syndrome. 318. A method of reducing the possibility of onset of conditions associated with elevated 10 Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon comprising administering a compound comprising a peptide sequence which binds to antibody to clara cell protein. 319 A method of reducing the possibility of nn^et of conditions -ed with elevated 15 Tascac Necrosis Factor (TNF), interieckm 1 or 2 and/or fcierferon as recited in claim 318, whereto said at least one compound consists of said sequence which bmds to antibody to c^ara cell protein. 320. A method of reducing the possibility of onset of conditions associated with elevated 20 Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 318, wherein said at least one compound consists of: S3 (1) a first residue consisting of said sequence which binds to antibody to clara cell protein; and (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 321. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 320, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 322. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 320 or claim 321, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or S3 N-tsrssml ead cf first re-ridue. Λ mcmcc of renucksg me possibility oi treact of conditions associated with elevated Tcmonr Necrosis Factor (TNF), interleukin 1 or 2 and/or Interferon as recited in any one of claims 320 - 322, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 324. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 320 - 322, wherein said sugar residue consists of heparin. 5 325. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 320 - 322, wherein said fatty acid residue is selected from the group consisting of Cj - C 20 fatty acid. 10 326. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 318 - 325, wherein said amount of at least one compound is sufficient to produce an elevation in T 8 count or T 4 count. 15 327. A method of reducing the pcssfeih^ of onse: ri conditions associated with elevated TunxMar Necrosis Factor (TNFi. iasadeukm 1 or ’ --.d Interferon as recited si any «se nt ciam» · ·’ * · wissxes: to said patient in piasma, said compound being present in said plasma m a concentration of from about 10 to about fOOOcc of ssid compound per ml of plasma. “Vi 328. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 318 - 327, wherein said compound is administered to said patient in a dosage in the range of from about lOpg to 20, OOOpg per kilogram of body weight of said patient. 329. A method of reducing the possibility of onset of conditions associated with elevated 5 Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 318 - 328, wherein said patient is a neonate and said administering is effected prior to delivery of said neonate and/or during delivery of said neonate. 330. A method of reducing the possibility of onset of conditions associated with elevated 10 Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 318 - 329, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 331. A method m redticmg the possibility of onset of conditions associated with elevaisd N«5sm bassor frtterkxk.c ί or 2 arsi'or Interferon is in ciaes 330. wfceresn said recombinant ceil line is a marnmahan cell line, an wsea. cell line or a bacterial cell line. 332. A method of reducing the possibility of onset of conditions associated with elevated 20 Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 318 - 331, further comprising administering to said patient at least one antiviral compound and/or at least one immune altering compound. 333. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in claim 332, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 334. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 318 - 333, wherein said patient is a human. 10 335. A method of reducing the possibility of onset of conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon as recited in any one of claims 318 - 334, wherein said patient is an animal. 336. A method of reducing the possibility of onset of eondmons associated wiih elevaied i 5 Tumore Necrosis Factor (TNFk Inicdeukis 1 or 2 or isterfcron as recited in any «se of clams 318-335, wherein said condition may cause wastmg syndrome. 337. A method Of tOtXUNzXUg the possibility of pre-term labour in a patient who has received other medication causing as a side effect inducement of labour by administering a 20 compound comprising a peptide sequence which binds to antibody to clara cell protein. 338. A method of reducing the possibility of pre-term labour as recited in claim 337, wherein said at least one compound consists of said sequence which binds to antibody to clara cell protein. 5 339. A method of reducing the possibility of pre-term labour as recited in claim 337, wherein said at least one compound consists of: (1) a first residue consisting of said sequence which binds to antibody to clara cell protein; and (2) at least one adjunct residue, 10 said at least one adjunct residue being attached to said first residue. 340. A method of reducing the possibility of pre-term labour as recited in claim 339, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino aciu residue, (2) a sugar residue, (3) a fatty acid residue and (4) 3 nucleotide secuence residue comprising at least one nucleotide residue 341. A method of reducing the possibility of prt-isrs: labour as recited in claim 339 or claim 340, wherein said at least one adjunct residue is covalently bonded to said first residue at 20 a C-terminal or an N-terminal end of said first residue. LA β Q Ο 3 Ο 3 342. A method of reducing the possibility of pre-term labour as recited in any one of claims 339 - 341, wherein said peptide sequence residue consists of albumin, Iactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 5 343. A method of reducing the possibility of pre-term labour as recited in any one of claims 339 - 341, wherein said sugar residue consists of heparin. 344. A method of reducing the possibility of pre-term labour as recited in any one of claims 339 - 341, wherein said fatty acid residue is selected from the group consisting of C, 10 C 2Q fatty acid. 345. A method of reducing the possibility of pre-term labour as recited in any one of claims 337 - 344, wherein said amount of a least one compound is sufficient to produce an elevation in aipha-feto protein s pie 346. A method of reducing me of pre-term labour sr earned m any one of claims 337 - 345. wherein sa*d cttzp&zxl is arimmiCereri to said paries: in plasma, sa*d compound being present m said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 347. A method of reducing the possibility of pre-term labour as recited in any one of claims 337 - 346, wherein said compound is administered to said patient in a dosage in the range of from about lOpg to 20, OOOgg per kilogram of body weight of said patient. 348. A method of reducing the possibility of pre-term labour as recited in any one of claims 337 - 347, wherein said patient is displaying cachexia. 5 349. A method of reducing the possibility of pre-term labour as recited in any one of claims 337 - 348, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 350. A method of reducing the possibility of pre-term labour as recited in claim 349, wherein 10 said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 351. A method of reducing the possibility of pre-term labour as recited in any one of claims 337 - 350, further comprising administering io said patient at least one anti-viral 15 compound and or at least one immune alterme ' 352. A method of rsds-cdig the possibility uf pre-term labour as recited m claim 351, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor, 20 353. A method of reducing the possibility of pre-term labour as recited in any one of claims 337 - 352, wherein said patient is a human. 354. A method of reducing the possibility of pre-term labour as recited in any one of claims 337 - 353, wherein said patient is an animal. 355. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome in 5 a patient in need of such treatment comprising administering to said patient at least one compound comprising a peptide sequence which binds to antibody to clara cell protein. 356. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in claim 355, wherein said at least one compound consists of said sequence which 10 binds to antibody to clara cell protein or part thereof. 357. A method of treating Inflammatory bowel disease and/or respiratory' distress syndrome as recited in claim 355, wherein said at least one compound consists of: (!) a first residue consisting of said sequence winch binds to ar/foody to clara cell 15 pnxeme atsi (2) at least one adjunct ret- . said at least one ad; i·' being attached to said first residue. 358. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as 20 recited in claim 357, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. £000303 359. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in claim 357 or claim 358, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 360. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 357 - 359, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 361. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 357 - 359, wherein said sugar residue consists of heparin. λ method of treating Icfl 4 **“ oiid/θΓ rCs^ii aiCs j ilisticaa» iyndrc recited in am one of claims 357 - 359. * herein said fatrv and residue is selected from the group consisting of C, - C& fetty acid. 363. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 355 - 362, wherein said amount of at least one compound is 20 sufficient to produce an elevation in T g count or T 4 count. 364. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 355 - 363, wherein said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 365. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 355 - 364, wherein said compound is administered to said patient in a dosage in the range of from about lOpg to 20, OOOpg per kilogram of body weight of said patient. 366. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 355 - 365, wherein said patient is suffering from wasting syndrome. 367. A method of treating Infiammatory bowel disease and/or respiratory distress syndrome as recited ;n any one ?f claims 355 - 366. wherein said peptide sequence is produced synthetically or is produced .... -mbrnant cell line. 368. A method of treatioc 60^c disease and cr recited in claim 367, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 5. 11= B 8 a j Q 5 369. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 355 - 368, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 5 370. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in claim 369, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 371. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as 10 recited in any one of claims 355 - 370, wherein said patient is a human. 372. A method of treating Inflammatory bowel disease and/or respiratory distress syndrome as recited in any one of claims 355 - 371, wherein said patient is an animal. -♦ Γ *» » S . 20 A method of treating wasting syndrome in a patient in need of such treatment, composing administering to said padsnt & least one compound in an amount which is eSeenve for said treatment of said wasting syndrome, said comprising a pepuk sequence selected from the group consisting of: -SEQ ID NO. 1 TO SEQ ID NO. 134 -conservative variants of SEQ ID NO. 1 TO SEQ ID NO. 134 which binds to antibody to Clara cell protein. 374. A method of treating wasting syndrome as recited in claim 1, wherein said at least one compound consists of: -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a part of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said part of a sequence having at least four amino acid residues; -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 , said portion of a sequence having at least four amino acid residues.] said sequence which binds to antibody to clara cell protein. 375. A method of treating wasting syndrome as recited in claim 1, wherein said at least one compound consists of: (1) a first residue consisting of: -a residue of a peptide sequence sc.ccied from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a conservative variant of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 said sequence which binds to antibody to Clara cell protein; and (2) at least one adjunct residue, 5 said at least one adjunct residue being attached to said first residue. 376. A method of treating wasting syndrome as recited in claim 3, wherein said at least one adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue 10 and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 377. A method of treating wasting syndrome as recited in claim 3 or claim 4, wherein said at least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 378. A method of treating wasting syndrome as recited in any one of claims 3-5, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 20 379. A method of treating wasting syndrome as recited in any one of claims 3 - 5, wherein said sugar residue consists of heparin. 380. A method of treating wasting syndrome as recited in any one of claims 3-5, wherein said fatty acid residue is selected from the group consisting of C, - C 20 fatty acid. 381. A method of treating wasting syndrome as recited in any one of claims 1 - 8, wherein 5 said amount of at least one compound is sufficient to produce an elevation in T g count or T 4 count of at least about 10% over pre-treatment levels in said patient after one month of therapy. 382. A method of treating wasting syndrome as recited in any one of claims 1-9, wherein 10 said compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 383. A method of treating wasting syndrome as recited in any one of claims 1 - 10, wherein 6. 15 said compound is administered to said patient in a dosage in the range of from about 10pg to 20, OOOpg per kilogram of body weight of said patient. 384. A method of treating wasting syndrome as recited in any one of claims 1-11, wherein said patient is a neonate and said administering is effected prior to delivery of said 7. 20 neonate and/or during delivery of said neonate. 385. A method of treating wasting syndrome as recited in any one of claims 1 - 12, wherein said peptide sequence is produced synthetically or is produced from a recombinant cell line. 5 386. A method of treating wasting syndrome as recited in claim 13, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 387. A method of treating wasting syndrome as recited in any one of claims 1 - 14, further comprising administering to said patient at least one anti-viral compound and/or at least 10 one immune altering compound. 388. A method of treating wasting syndrome as recited in claim 15, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 15 389. A method of treating wasting syndrome as recited in any one of claims 1-16, wherein said patient is a human. 390. A method of treating wasting syndrome as recited in any one of claims 1-17, wherein said patient is an animal. 391. A method of treating wasting syndrome in a patient in need of such treatment, comprising administering to said patient at least one compound in an amount which is effective for said treatment of said wasting syndrome, said compound comprising a peptide sequence selected from the group consisting of: -SEQ ID NO. 1 TO SEQ ID NO. 134 -conservative variants of SEQ ID NO. 1 TO SEQ ID NO. 134 . 10 392. A method of treating wasting syndrome as recited in claim 1, wherein said at least one compound consists of: -a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 -a part of a sequence selected from the group consisting of SEQ ED NO. 1 TO SEQ ID NO. 134 , said part of a sequence having at least four amino acid residues; 15 -a conservative variant of a sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a conservative variant of a portion of a sequence selected from the group consisting of SEQ ED NO. 1 TO SEQ ED NO. 134 , said portion of a sequence having at least four amino acid residues. 393. A method of treating wasting syndrome as recited in claim 1, wherein said at least one compound consists of: (1) a first residue consisting of: -a residue of a peptide sequence selected from the group consisting of SEQ ED NO. 1 TO SEQ ID NO. 134 -a residue of a part of a peptide sequence selected from the group consisting of 5 SEQ ID NO. 1 TO SEQ ID NO. 134 -a residue of a conservative variant of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 or -a residue of a conservative variant of a part of a peptide sequence selected from the group consisting of SEQ ID NO. 1 TO SEQ ID NO. 134 and 10 (2) at least one adjunct residue, said at least one adjunct residue being attached to said first residue. 394. A method of treating wasting syndrome as recited in claim 3, wherein said at least one 15 adjunct residue is selected from the group consisting of (1) a peptide sequence residue comprising at least one amino acid residue, (2) a sugar residue, (3) a fatty acid residue and (4) a nucleotide sequence residue comprising at least one nucleotide residue. 395. A method of treating wasting syndrome as recited in claim 3 or claim 4, wherein said at 20 least one adjunct residue is covalently bonded to said first residue at a C-terminal or an N-terminal end of said first residue. 100 396. A method of treating wasting syndrome as recited in any one of claims 3-5, wherein said peptide sequence residue consists of albumin, lactoferrin or alpha feto protein, urinary protein, urinary protein 1 and/or uteroglobin. 5 397. A method of treating wasting syndrome as recited in any one of claims 3-5, wherein said sugar residue consists of heparin. 398. A method of treating wasting syndrome as recited in any one of claims 3-5, wherein said fatty acid residue is selected from the group consisting of Cj - C 20 fatty acid. 399. A method of treating wasting syndrome as recited in any one of claims 1-8, wherein said amount of at least one compound is sufficient to produce an elevation in T g count or T. count. 400. A method of treating wasting syndrome as recited in any one of claims 1-9, wherein said 15 compound is administered to said patient in plasma, said compound being present in said plasma in a concentration of from about 10 to about 5000pg of said compound per ml of plasma. 401. A method of treating wasting syndrome as recited in any one of claims 1-10, wherein 20 said compound is administered to said patient in a dosage in the range of from about 10pg to 20, OOOpg per kilogram of body weight of said patient. 101 402. A method of treating wasting syndrome as recited in any one of claims 1-11, wherein said patient is suffering from Alzheimer’s disease. 403. A method of treating wasting syndrome as recited in any one of claims 1-12, wherein 5 said peptide sequence is produced synthetically or is produced from a recombinant cell line. 404. A method of treating wasting syndrome as recited in claim 13, wherein said recombinant cell line is a mammalian cell line, an insect cell line or a bacterial cell line. 405. A method of treating wasting syndrome as recited in any one of claims 1-14, further comprising administering to said patient at least one anti-viral compound and/or at least one immune altering compound. 15 406. A method of treating wasting syndrome as recited in claim 15, wherein said immune altering compound is a protease inhibitor or a reverse transcriptase inhibitor. 407. A method of treating wasting syndrome as recited in any one of claims 1-16, wherein said patient is a human. 408. A method of treating wasting syndrome as recited in any one of claims 1-17, wherein said patient is an animal. 102 990^05 409. A method of treating or reducing the likelihood of a wasting syndrome in a human patient suffering or at risk for suffering said infection, comprising administering to said subject a clinically effective amount of CLARA CELL PROTEIN Pl(CC10). 410. A method according to claim 1, wherein said effective amount is 10-5000μ§/πύ cone. In plasma. 411. A method according to claim 9, wherein said effective amount is administered in a 10 dosage ranging between about 1 Ogg and 20, ΟΟΟμβ per Kilogram of body weight. 412. Clara cell protein Pl (CC10) in a therapeutic, sustained-release form. 413. A method of treating or reducing the developing likelihood of Cachexia in a patient 15 following surgery, comprising administering to said patient a clinically effective amount of Clara Cell Protein in either its native, recombinant or synthetic forms. 414. A method of ameliorating the immune damage and disease progression in patients with elevated Tumour Necrosis Factor (TNF) which comprises the administration to said 20 patient a clinically effective amount of Clara Cell Protein in either its native, recombinant or synthetic forms. 103 ΙΕΟ Ο Ο a 0 3 415. A method according to claim 1, 12, & 13 wherein said therapeutic peptide is attached to a carrier molecule either another peptide e.g. albumin, a sugar, fatty acid or nucleotide molecules. 5 416. A method according to Claim 1, 12 & 13 wherein said therapeutic peptide is administered alone or in conjunction with known anti-viral or immune altering therapeutics. 417. A method according to claim 1, 12 & 13 wherein the products of said therapeutics 10 peptide is produced within the patient by the transformation of patients own cells by the incorporation of the genetic code (DNA) or (RNA) for to allow endogenous synthesis of Clara Cell Protein. 418. A method according to claim 16 wherein the DNA coding the Clara Cell Protein is 15 injected into the patients cells in situ (using current DNA vaccination) techniques without the need for in-vitro alteration and culture of the patient cells. 419 A method according to claims 3 , 4, 5, 23, 24, 25, 43, 44, 45, 61, 62, 63, 79, 80, 81, 97, 98, 115, 116, 117, 134, 135, 136, 153, 154, 155, 171, 172, 173, 189, 20 190, 191, 209, 210, 211, 229, 230, 231, 247, 248, 249, 265, 266, 267, 283, 284, 285, 301, 302, 303, 320, 321, 322, 339, 340, 341, 357, 358, 359, 375, 376, 377, 393, 394, 395, wherein the adjunct residue consists of one to eighty amino acids. 104 420 A method according to claims 3 , 4, 5, 23, 24, 25, 43, 44, 45, 61, 62, 63, 79, 80, 81, 97, 98, 115, 116, 117, 134, 135, 136, 153, 154, 155, 171, 172, 173, 189, 190, 191, 209, 210, 211, 229, 230, 231, 247, 248, 249, 265, 266, 267, 283, 284, 285, 301, 302, 303, 320, 321, 322, 339, 340, 341, 357, 358, 359, 375, 376, 377, 5 393, 394, 395 wherein the adjunct residue consists essentially of positive charged amino acids, 421 A method according to claims 3 , 4, 5, 23, 24, 25, 43, 44, 45, 61, 62, 63, 79, 80, 81, 97, 98, 115, 116, 117, 134, 135, 136, 153, 154, 155, 171, 172, 173, 189, 190, 191, 209, 210, 211, 229, 230, 231, 247, 248, 249, 265, 266, 267, 283, 284, 10 285, 301, 302, 303, 320, 321, 322, 339, 340, 341, 357, 358, 359, 375, 376, 377, 393, 394, 395 wherein the adjunct residue consists of one to twenty amino acids of positive charge. 422 A method according to claims 3 , 4, 5, 23, 24, 25, 43, 44, 45, 61, 62, 63, 79, 80, 81, 97, 98, 115, 116, 117, 134, 135, 136, 153, 154, 155, 171, 172, 173, 189, 15 190, 191, 209, 210, 211, 229, 230, 231, 247, 248, 249, 265, 266, 267, 283, 284, 285, 301, 302, 303, 320, 321, 322, 339, 340, 341, 357, 358, 359, 375, 376, 377, 393, 394, 395 wherein the adjunct residue contains blocks of two or more adjacent amino acids of positive charge. 423 A method according to claim 420, 421 and/or 422 wherein the positive charged amino 20 acid is either Histidine, Arginine and/or Lysine. 424 A method according to claims 1, 2, 3, 21, 22, 23, 41, 42, 43, 59, 60, 61, 77, 78, 79, 95, 96, 97, 113, 114, 115, 132, 133, 134, 151, 152, 153, 169, 170, 171, 187, 188, 189, 207, 208, 209, 227, 228, 229232, 247, 249, 250, 265, 266, 267, 281, 282, 283, 299, 300, 301, 105 IE Ο Ο 0 3 Ο 3 319, 320, 321, 337, 338, 339, 355, 356, 357, 373, 374, 375, 391, 392, 393, 413 and 414 wherein the peptide is co-administered with a plasma enhancing agent for the said peptide 425 A method according to claims 1, 2, 3, 21, 22, 23, 41, 42, 43, 59, 60, 61, 77, 78, 79, 5 95, 96, 97, 113, 114, 115, 132, 133, 134, 151, 152, 153, 169, 170, 171, 187, 188, 189, 207, 208, 209, 227, 228, 229232, 247, 249, 250, 265, 266, 267, 281, 282, 283, 299, 300, 301, 319, 320, 321, 337, 338, 339, 355, 356, 357, 373, 374, 375, 391, 392, 393, 413 and 414 wherein the peptide is co-administered with Probenecid 426 A method according to claims 1, 2, 3, 21, 22, 23, 41, 42, 43, 59, 60, 61, 77, 78, 79, 95, 10 96, 97, 113, 114, 115, 132, 133, 134, 151, 152, 153, 169, 170, 171, 187, 188, 189, 207, 208, 209, 227, 228, 229232, 247, 249, 250, 265, 266, 267, 281, 282, 283, 299, 300, 301, 319, 320, 321, 337, 338, 339, 355, 356, 357, 373, 374, 375, 391, 392, 393, 413 and 414 wherein one or more of the said peptides are attached to a PEG molecule. 427 A method according to claimsl, 2, 3, 21, 22, 23,41,42,43, 59, 60, 61, 77, 78, 79, 95, 96, 15 97, 113, 114, 115, 132, 133, 134, 151, 152, 153, 169, 170, 171, 187, 188, 189,207,208, 209,227, 228, 229232, 247, 249, 250, 265, 266, 267, 281, 282, 283, 299, 300, 301, 319, 320, 321, 337, 338, 339, 355, 356, 357, 373, 374, 375, 391, 392, 393, 413 and 414wherein two or more of the said peptides are complexed together.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20000303A IE20000303A1 (en) | 2000-04-13 | 2000-04-13 | Peptides for Therapeutic use |
| PCT/IB2000/000895 WO2000072868A2 (en) | 1999-06-01 | 2000-06-01 | Peptides for therapeutic use |
| AU58367/00A AU5836700A (en) | 1999-06-01 | 2000-06-01 | Peptides for therapeutic use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20000303A IE20000303A1 (en) | 2000-04-13 | 2000-04-13 | Peptides for Therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IE20000303A1 true IE20000303A1 (en) | 2003-02-19 |
Family
ID=27637730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE20000303A IE20000303A1 (en) | 1999-06-01 | 2000-04-13 | Peptides for Therapeutic use |
Country Status (1)
| Country | Link |
|---|---|
| IE (1) | IE20000303A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
-
2000
- 2000-04-13 IE IE20000303A patent/IE20000303A1/en not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| US11903916B2 (en) | 2020-04-10 | 2024-02-20 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2310931T3 (en) | HUMAN ALPHA INTERFER ANALOGS OF LOW TOXICITY. | |
| IFNB Multiple Sclerosis Study Group | Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial | |
| EP2875826B1 (en) | Composition for preventing or treating sepsis | |
| US6361769B1 (en) | Stimulation of host defense mechanisms against viral challenges | |
| JP2813017B2 (en) | How to reduce side effects of cancer therapy | |
| US20040009939A1 (en) | Methods of enhancing immune induction involving MDA-7 | |
| JP2019528753A5 (en) | ||
| JP2012529440A (en) | Interferon administration to prevent or treat pathogen infection | |
| WO2000040273A2 (en) | Treatment of viral diseases using an interferon omega expressing polynucleotide | |
| CN112135623A (en) | Compositions and methods related to the treatment of diseases | |
| JP5547640B2 (en) | Prostate cancer treatment / prevention agent | |
| PT87997B (en) | A method for the preparation of U.S.P Pharmaceutical Compounds for the Correction of Absorbent Metabolic Pathways Associated with Decontrolled Growth Cycles of Tumor Cells and Viruses Containing Double-stranded RNA | |
| KR20160113302A (en) | Compositions and methods for treating neutropenia | |
| WO2005018542A2 (en) | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects | |
| EP4121092B1 (en) | Hybrid interferons for treating viral infections | |
| JP2019524753A (en) | Use of IL-12 as a replacement immunotherapeutic | |
| IE20000303A1 (en) | Peptides for Therapeutic use | |
| RU2519763C9 (en) | Method for immune therapy of oncological diseases and pharmaceutical compositions of oncolytic sendai virus | |
| JP5692933B2 (en) | Tumor treatment with immunostimulatory HIV Tat derivative polypeptide | |
| CN101244263A (en) | Mixtures comprising mixed interferon-alpha subtypes | |
| EP2370088B1 (en) | Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof | |
| JP3806444B2 (en) | Stimulation of host defense mechanisms against viral infection | |
| JPH06340549A (en) | Therapeutic agent for feline respiratory organ disease and therapeutic method using the therapeutic agent | |
| US20200038440A1 (en) | Short-term activated dc1s and methods for their production and use | |
| KR100530125B1 (en) | Treatment and treatment of refractory dermatitis in dogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Patent lapsed through non-payment of renewal fee |